“…Despite their potent and selective antiviral activity in vitro, the rhinovirus inhibitors that have so far been the subject of clinical studies, viz., enviroxime (21,26,28,33), 4',6-dichloroflavan (32), and some isoquinoline derivatives (40,43), have proven of little, if any, value in the prophylaxis or therapy of rhinovirus infections in volunteers. No significant effects on rhinorrhea, clinical score, or virus excretion were noted whether the compounds were given intranasally (21,26,28,33,43) or orally (32,40 The fine editorial assistance of Christiane Callebaut is gratefully acknowledged.…”